Clinical Trial

A Substudy of the Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The prevention of perioperative anemia has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone tumor surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial, and intraoperative fluid administration strategy is an important confounding factor. The HEAL trial will assess whether ANH will improve postoperative hemoglobin levels when applying goal-directed fluid therapy in patients undergoing bone tumor surgery.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT06881498
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Bone Tumor, Acute Normovolemic Hemodilution, Goal-Directed Fluid Therapy
Enrollment 32 participants
Start Date 2024-06-07
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-04-15